Mineral trioxide aggregate (MTA) vs 3Mixtatin
It is very uncertain whether mineral trioxide aggregate (MTA) changes clinical failure compared with 3Mixtatin (very low certainty).
- RR 0.67 [0.12, 3.78]1 study · 160 participantsVery low
It is very uncertain whether mineral trioxide aggregate (MTA) changes clinical failure compared with 3Mixtatin (very low certainty).
Mineral trioxide aggregate (MTA) may leads to lower clinical failure compared with 3Mix (ciprofloxacin + metronidazole + minocycline) (low certainty).
Mineral trioxide aggregate (MTA) probably leads to lower clinical failure compared with full strength or 1:5 diluted formocresol (FC) (moderate certainty).
Mineral trioxide aggregate (MTA) showed no clear difference in clinical failure compared with portland cement (PC); GRADE not reported.
Mineral trioxide aggregate (MTA) probably leads to lower clinical failure compared with calcium hydroxide (CH) (moderate certainty).
Mineral trioxide aggregate (MTA) showed no clear difference in clinical failure compared with sodium hypochlorite (NaOCl); GRADE not reported.
Mineral trioxide aggregate (MTA) may leads to lower clinical failure compared with simvastatin (low certainty).
It is very uncertain whether mineral trioxide aggregate (MTA) changes clinical failure compared with ferric sulphate (FS) (very low certainty).
Mineral trioxide aggregate (MTA) showed no clear difference in clinical failure compared with enamel matrix derivative (EMD); GRADE not reported.
Mineral trioxide aggregate (MTA) showed no clear difference in clinical failure compared with zinc oxide and eugenol (ZOE); GRADE not reported.